Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.65 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.65 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.65 |
| ▸ | GAPDH | P04406 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | STAT6 | P42226 | 1/20 | 0.65 |
| ▸ | PI4KA | P42356 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.65 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.65 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.65 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.65 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20418948 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2ADORA2AADORA2BDPP4MEN1 | |
| SCHEMBL967479 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2ADORA2AADORA2BDPP4MEN1 | |
| SCHEMBL29323163 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2ADORA2AADORA2BDPP4MEN1 | |
| SCHEMBL20419184 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2ADORA2AADORA2BDPP4MEN1 | |
| SCHEMBL12031134 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2ADORA2AADORA2BDPP4MEN1 | |
| SCHEMBL17780621 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2ADORA2AADORA2BDPP4MEN1 | |
| SCHEMBL31376058 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2ADORA2AADORA2BDPP4MEN1 | |
| SCHEMBL11124342 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2ADORA2AADORA2BDPP4MEN1 | |
| Hydrochloric Acid SCHEMBL30582654 | 0.99 | SMN1; SMN2 (0.67) | SMN1; SMN2ADORA2AADORA2BDPP4MEN1 | |
| SCHEMBL12031334 | 0.90 | SMN1; SMN2 (0.62) | SMN1; SMN2ADORA2AADORA2BDPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340848-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | claimed |
| EP-1539188-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | claimed |
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | claimed |
| WO-2002057425-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | claimed |
| EP-0038568-B1 | SYNTHESIS OF DEAZAPURINE NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-07-20 | — | — | EP | claimed |
| US-4347315-A | FORMING 4-SUBSTITUTED 1-B-D-RIBOFURANOSYL-1H-IMIDAZO(4,5-C)PYRIDINES FROM RIBOSE-1-PHOSPHATE | BURROUGHS WELLCOME CO. (US) | 1982-08-31 | — | — | US | claimed |
| US-4322411-A | Anti-inflammatory nucleosides | BURROUGHS WELLCOME CO. (US) | 1982-03-30 | — | — | US | claimed |
| EP-0038567-A1 | Deazapurine nucleoside, formulations thereof, and use thereof in therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-10-28 | — | — | EP | claimed |
| EP-0038568-A1 | Synthesis of deazapurine nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-10-28 | — | — | EP | claimed |
| EP-4746905-A1 | RSV VACCINE | Astrazeneca AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026104647-A1 | VACCINE | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4709417-A2 | POLYNUCLEOTIDES ENCODING NOROVIRUS VP1 ANTIGENS AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-4322411-A | Anti-inflammatory nucleosides | BURROUGHS WELLCOME CO. (US) | 1982-03-30 | — | — | US | disclosed |
| EP-0038567-A1 | Deazapurine nucleoside, formulations thereof, and use thereof in therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-10-28 | — | — | EP | disclosed |
| EP-0038567-A1 | Deazapurine nucleoside, formulations thereof, and use thereof in therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-10-28 | — | — | EP | disclosed |
| EP-0038568-A1 | Synthesis of deazapurine nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-10-28 | — | — | EP | disclosed |
| EP-0038568-A1 | Synthesis of deazapurine nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | SMN1; SMN2 4031/4885ADORA2A 174/4885ADORA2B 541/4885 |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | SMN1; SMN2 3740/4885ADORA2A 395/4885ADORA2B 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.